TriSalus Life Sciences, Inc. 8-K

What Happened TriSalus Life Sciences, Inc. filed an 8-K on February 9, 2026 disclosing that Dr. Arjun “JJ” Desai resigned from the Company’s Board of Directors effective February 3, 2026. The company announced that Michael P. Stansky was appointed to the Board effective February 4, 2026 and a press release dated February 9, 2026 was issued to announce the appointment.

Key Details

• Dr. Arjun “JJ” Desai resigned effective February 3, 2026; the resignation was not due to any disagreement with the Company on operations, policies or practices.
• Michael P. Stansky joined the Board effective February 4, 2026 and brings roughly 40 years of investment management and healthcare experience.
• Mr. Stansky will serve on the Audit Committee, Compensation Committee and Science and Technology Committee.
• The company reported no related-party transactions with Mr. Stansky that would require disclosure under Item 404(a) of Regulation S-K; a press release (Exhibit 99.1) accompanies the filing.

Why It Matters A director change can affect corporate governance and board expertise. Investors should note the continuity—Desai’s resignation was not due to disagreement—and that the company added an experienced healthcare and investment executive to key committees overseeing finance, compensation and science/technology issues. The filing and press release provide the official record of these governance changes.